Patients After Orthotopic Heart Transplantation With COVID-19: Are We Fast Enough With Vaccinations?
Patients after orthotopic heart transplantation (HTx) are especially susceptible to infections owing to permanent need for immunosuppression. Vaccinations against COVID-19 have been available since January 2021 and are recommended in organ recipients. The aim of this study was to analyze COVID-19 su...
Saved in:
| Published in: | Transplantation proceedings Vol. 54; no. 4; pp. 897 - 900 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Elsevier Inc
01-05-2022
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Patients after orthotopic heart transplantation (HTx) are especially susceptible to infections owing to permanent need for immunosuppression. Vaccinations against COVID-19 have been available since January 2021 and are recommended in organ recipients.
The aim of this study was to analyze COVID-19 susceptibility and mortality in HTx and number of patients with COVID-19 previously vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
We analyzed a whole cohort of 552 patients after HTx who were SARS-CoV-2 positive and remained under surveillance of the transplantation center during March 2020 to September 2021.
Among 552 patients after HTx, 10 were COVID-19 survivors prior to transplantation and 103 had SARS CoV-2 infection after transplantation.
Mean age of patients with COVID-19 was 55.6 (±14) years, and mean time from transplantation to SARS-CoV-2 infection was 2856 (±2596) days (range, 16-9569 days; interquartile range, 397-4763 days). Among the patients who were COVID-19 positive, 15 were asymptomatic, 10 died, and 51 infections occurred in the era of vaccinations.
In the group of patients who were positive for COVID-19 in 2021, 6 received only a single dose of the mRNA vaccine and 3 were vaccinated twice. Among the vaccinated patients with COVID-19, 2 died of severe COVID-19: 1 after a single dose and 1 after 2 standard doses of the vaccine.
We observed high susceptibility to SARS-CoV-2 infection in the group of patients after HTx. The majority of patients infected in 2021 did not received the vaccine. Vaccination does not fully protect against severe COVID-19 in patients after HTx. |
|---|---|
| AbstractList | Patients after orthotopic heart transplantation (HTx) are especially susceptible to infections owing to permanent need for immunosuppression. Vaccinations against COVID-19 have been available since January 2021 and are recommended in organ recipients.
The aim of this study was to analyze COVID-19 susceptibility and mortality in HTx and number of patients with COVID-19 previously vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
We analyzed a whole cohort of 552 patients after HTx who were SARS-CoV-2 positive and remained under surveillance of the transplantation center during March 2020 to September 2021.
Among 552 patients after HTx, 10 were COVID-19 survivors prior to transplantation and 103 had SARS CoV-2 infection after transplantation. Mean age of patients with COVID-19 was 55.6 (±14) years, and mean time from transplantation to SARS-CoV-2 infection was 2856 (±2596) days (range, 16-9569 days; interquartile range, 397-4763 days). Among the patients who were COVID-19 positive, 15 were asymptomatic, 10 died, and 51 infections occurred in the era of vaccinations. In the group of patients who were positive for COVID-19 in 2021, 6 received only a single dose of the mRNA vaccine and 3 were vaccinated twice. Among the vaccinated patients with COVID-19, 2 died of severe COVID-19: 1 after a single dose and 1 after 2 standard doses of the vaccine.
We observed high susceptibility to SARS-CoV-2 infection in the group of patients after HTx. The majority of patients infected in 2021 did not received the vaccine. Vaccination does not fully protect against severe COVID-19 in patients after HTx. BACKGROUNDPatients after orthotopic heart transplantation (HTx) are especially susceptible to infections owing to permanent need for immunosuppression. Vaccinations against COVID-19 have been available since January 2021 and are recommended in organ recipients.AIMThe aim of this study was to analyze COVID-19 susceptibility and mortality in HTx and number of patients with COVID-19 previously vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).PATIENTS AND METHODSWe analyzed a whole cohort of 552 patients after HTx who were SARS-CoV-2 positive and remained under surveillance of the transplantation center during March 2020 to September 2021.RESULTSAmong 552 patients after HTx, 10 were COVID-19 survivors prior to transplantation and 103 had SARS CoV-2 infection after transplantation. Mean age of patients with COVID-19 was 55.6 (±14) years, and mean time from transplantation to SARS-CoV-2 infection was 2856 (±2596) days (range, 16-9569 days; interquartile range, 397-4763 days). Among the patients who were COVID-19 positive, 15 were asymptomatic, 10 died, and 51 infections occurred in the era of vaccinations. In the group of patients who were positive for COVID-19 in 2021, 6 received only a single dose of the mRNA vaccine and 3 were vaccinated twice. Among the vaccinated patients with COVID-19, 2 died of severe COVID-19: 1 after a single dose and 1 after 2 standard doses of the vaccine.CONCLUSIONWe observed high susceptibility to SARS-CoV-2 infection in the group of patients after HTx. The majority of patients infected in 2021 did not received the vaccine. Vaccination does not fully protect against severe COVID-19 in patients after HTx. Patients after orthotopic heart transplantation (HTx) are especially susceptible to infections owing to permanent need for immunosuppression. Vaccinations against COVID-19 have been available since January 2021 and are recommended in organ recipients. The aim of this study was to analyze COVID-19 susceptibility and mortality in HTx and number of patients with COVID-19 previously vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We analyzed a whole cohort of 552 patients after HTx who were SARS-CoV-2 positive and remained under surveillance of the transplantation center during March 2020 to September 2021. Among 552 patients after HTx, 10 were COVID-19 survivors prior to transplantation and 103 had SARS CoV-2 infection after transplantation. Mean age of patients with COVID-19 was 55.6 (±14) years, and mean time from transplantation to SARS-CoV-2 infection was 2856 (±2596) days (range, 16-9569 days; interquartile range, 397-4763 days). Among the patients who were COVID-19 positive, 15 were asymptomatic, 10 died, and 51 infections occurred in the era of vaccinations. In the group of patients who were positive for COVID-19 in 2021, 6 received only a single dose of the mRNA vaccine and 3 were vaccinated twice. Among the vaccinated patients with COVID-19, 2 died of severe COVID-19: 1 after a single dose and 1 after 2 standard doses of the vaccine. We observed high susceptibility to SARS-CoV-2 infection in the group of patients after HTx. The majority of patients infected in 2021 did not received the vaccine. Vaccination does not fully protect against severe COVID-19 in patients after HTx. |
| Author | Przybyłowski, Piotr Kuczaj, Agnieszka |
| Author_xml | – sequence: 1 givenname: Agnieszka orcidid: 0000-0002-9462-0467 surname: Kuczaj fullname: Kuczaj, Agnieszka email: agnieszka.kuczaj@gmail.com organization: Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland – sequence: 2 givenname: Piotr surname: Przybyłowski fullname: Przybyłowski, Piotr organization: Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35414424$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUctuGyEURVGqxHn8QoW66mYcYPDMkEUry3lZsuQs8lgiBu7EWDa4gCP178vErpXuKl0JEOfB4ZyhY-cdIPSNkiEltLpaDlNQLm6C1wBmyAhjQ9IPO0ID2tRlwSpWHqMBIZwWtOSjU3QW45LkM-PlCTotR5zyvB8g86iSBZciHncJAp6HtPDJb6zGD6BCwk8fVivlUgZ6h19tWuDJ_GV6U1BxjccB8CvgOxUTvnV--7bYIV6U1tZ9UOLPC_SlU6sIl_v1HD3f3T5NHorZ_H46Gc8KzWmdiq4rO9JSpSqodY5gGLRaM1oKIljbsppXNR9VFdFKmY5o1nIjmMipuGkaI8pz9GOnu9m2azA65wpqJTfBrlX4Lb2y8t8bZxfyzb_LRjCSTbLA971A8L-2EJNc26hhleOD30bJKi6EqHjDMvR6B9XBxxigO9hQIvua5FJ-rkn2NUnST0_--vmhB-rfXjLgZgeA_F3vFoKMOtekwdgAOknj7f_4_AHrt62O |
| CitedBy_id | crossref_primary_10_1016_j_transproceed_2024_04_014 |
| Cites_doi | 10.1111/tid.13705 10.1007/s00392-020-01722-w 10.1016/j.jiph.2021.06.020 10.1111/tid.13628 10.1038/s41581-021-00491-7 10.1056/NEJMoa2101765 10.1016/j.cmi.2021.04.028 10.1016/j.jchf.2020.10.009 10.1186/s40249-021-00915-3 10.1093/ckj/sfab125 10.1111/ajt.16818 10.1056/NEJMoa2108891 10.1093/cid/ciab580 |
| ContentType | Journal Article |
| Copyright | 2022 Elsevier Inc. Copyright © 2022 Elsevier Inc. All rights reserved. 2022 Elsevier Inc. All rights reserved. 2022 Elsevier Inc. |
| Copyright_xml | – notice: 2022 Elsevier Inc. – notice: Copyright © 2022 Elsevier Inc. All rights reserved. – notice: 2022 Elsevier Inc. All rights reserved. 2022 Elsevier Inc. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.1016/j.transproceed.2022.02.022 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2623 |
| EndPage | 900 |
| ExternalDocumentID | 10_1016_j_transproceed_2022_02_022 35414424 S0041134522002032 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1~. 1~5 29Q 3O- 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABBQC ABFRF ABJNI ABLJU ABLVK ABMAC ABMZM ABOCM ABXDB ABYKQ ACDAQ ACGFO ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W J5H K-O KOM L7B LCYCR M41 MO0 N9A O-L O9- OAUVE OK- OW- OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K UDS WH7 X7M XPP Y6R Z5R ZA5 ZGI ZXP ~G- AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c417t-ff3f0b1aa6e7c262d2ebcc2139092bb2746745660caadf0c2b4d9290044d88d93 |
| ISSN | 0041-1345 |
| IngestDate | Tue Sep 17 20:38:08 EDT 2024 Sat Oct 05 06:08:00 EDT 2024 Thu Sep 26 18:57:22 EDT 2024 Sat Nov 02 12:20:11 EDT 2024 Fri Feb 23 02:40:29 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | Copyright © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c417t-ff3f0b1aa6e7c262d2ebcc2139092bb2746745660caadf0c2b4d9290044d88d93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-9462-0467 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8920909 |
| PMID | 35414424 |
| PQID | 2649996482 |
| PQPubID | 23479 |
| PageCount | 4 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8920909 proquest_miscellaneous_2649996482 crossref_primary_10_1016_j_transproceed_2022_02_022 pubmed_primary_35414424 elsevier_sciencedirect_doi_10_1016_j_transproceed_2022_02_022 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-05-01 |
| PublicationDateYYYYMMDD | 2022-05-01 |
| PublicationDate_xml | – month: 05 year: 2022 text: 2022-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Transplantation proceedings |
| PublicationTitleAlternate | Transplant Proc |
| PublicationYear | 2022 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Bottio, Bagozzi, Fiocco (bib0010) 2021; 9 Schmidt, Klemis, Schub (bib0008) 2021; 21 Dagan, Barda, Kepten, Miron, Perchik, Katz (bib0004) 2021; 384 Ducloux, Colladant, Chabannes (bib0014) 2021; 14 Mazzola, Todesco, Drouin (bib0013) 2021; 74 Sewis Rzeczyposoplitej Polskiej.Szczepienie przeciwko COVID-19. Raport ze szczepień przeciwko COVID-19. Basic-Jukic, Jelicic (bib0007) 2021 [accessed 01.11.21]. Caillars, Thaunat (bib0012) 2021; 17 Lopez Bernal, Andrews, Charlotte Gower (bib0002) 2021; 385 Aslam, Adler, Mekeel (bib0005) 2021; 23 2021 [accessed 10.11.2021]. Joint statement about vaccine efficacy in organ transplant recipients Mariani, Acquila, Tripodi (bib0015) 2021; 14 Rivinius, ZiyaK (bib0009) 2020; 109 Liu, Qin, Liu (bib0003) 2021; 10 Rozen-Zvi, Yahav, Agur, Zingerman, Ben-Zvi, Atamna (bib0006) 2021; 27 Mazzola (10.1016/j.transproceed.2022.02.022_bib0013) 2021; 74 Caillars (10.1016/j.transproceed.2022.02.022_bib0012) 2021; 17 Bottio (10.1016/j.transproceed.2022.02.022_bib0010) 2021; 9 Rivinius (10.1016/j.transproceed.2022.02.022_bib0009) 2020; 109 10.1016/j.transproceed.2022.02.022_bib0011 10.1016/j.transproceed.2022.02.022_bib0001 Liu (10.1016/j.transproceed.2022.02.022_bib0003) 2021; 10 Lopez Bernal (10.1016/j.transproceed.2022.02.022_bib0002) 2021; 385 Mariani (10.1016/j.transproceed.2022.02.022_bib0015) 2021; 14 Dagan (10.1016/j.transproceed.2022.02.022_bib0004) 2021; 384 Basic-Jukic (10.1016/j.transproceed.2022.02.022_bib0007) 2021 Aslam (10.1016/j.transproceed.2022.02.022_bib0005) 2021; 23 Schmidt (10.1016/j.transproceed.2022.02.022_bib0008) 2021; 21 Rozen-Zvi (10.1016/j.transproceed.2022.02.022_bib0006) 2021; 27 Ducloux (10.1016/j.transproceed.2022.02.022_bib0014) 2021; 14 |
| References_xml | – volume: 14 start-page: 1560 year: 2021 end-page: 1562 ident: bib0015 article-title: Antibodies against receptor binding domain of SARS-CoV-2 spike protein induced by BNT162b2 vaccine: results from a pragmatic, real-life study publication-title: J Infect Public Health contributor: fullname: Tripodi – volume: 14 start-page: 2270 year: 2021 end-page: 2272 ident: bib0014 article-title: Factors associated with humoral response after BNT162b2 mRNA COVID-19 vaccination in kidney transplant patients publication-title: Clin Kidney J contributor: fullname: Chabannes – volume: 27 start-page: 1173e year: 2021 ident: bib0006 article-title: Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study publication-title: Clin Microbiol Infect contributor: fullname: Atamna – volume: 74 start-page: 1093 year: 2021 end-page: 1096 ident: bib0013 article-title: Poor antibody response after two doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in transplant recipients publication-title: Clin Infect Dis contributor: fullname: Drouin – volume: 385 start-page: 585 year: 2021 end-page: 587 ident: bib0002 article-title: Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant publication-title: N Engl J Med contributor: fullname: Charlotte Gower – volume: 109 start-page: 1531 year: 2020 end-page: 1539 ident: bib0009 article-title: COVID19 among heart transplant recipients in Germany: a multicenter survey publication-title: Clin Res Cardiol contributor: fullname: ZiyaK – year: 2021 ident: bib0007 article-title: SARS-CoV-2 infection after two doses of mRNA vaccine in renal transplant recipients publication-title: Transpl Infect Dis contributor: fullname: Jelicic – volume: 9 start-page: 52 year: 2021 end-page: 61 ident: bib0010 article-title: COVID-19 in heart transplant recipients: a multicenter analysis of the Northern Italian outbreak publication-title: JACC Heart Fail contributor: fullname: Fiocco – volume: 10 start-page: 132 year: 2021 ident: bib0003 article-title: Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis publication-title: Infect Dis Poverty contributor: fullname: Liu – volume: 23 start-page: e13705 year: 2021 ident: bib0005 article-title: Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients publication-title: Transpl Infect Dis contributor: fullname: Mekeel – volume: 21 start-page: 3990 year: 2021 end-page: 4002 ident: bib0008 article-title: Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients publication-title: Am J Transplant contributor: fullname: Schub – volume: 384 start-page: 1412 year: 2021 end-page: 1423 ident: bib0004 article-title: BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting publication-title: N Engl J Med contributor: fullname: Katz – volume: 17 start-page: 785 year: 2021 end-page: 787 ident: bib0012 article-title: COVID-19 vaccination in kidney transplant recipients publication-title: Nat Rev Nephrol contributor: fullname: Thaunat – volume: 23 start-page: e13705 year: 2021 ident: 10.1016/j.transproceed.2022.02.022_bib0005 article-title: Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients publication-title: Transpl Infect Dis doi: 10.1111/tid.13705 contributor: fullname: Aslam – volume: 109 start-page: 1531 year: 2020 ident: 10.1016/j.transproceed.2022.02.022_bib0009 article-title: COVID19 among heart transplant recipients in Germany: a multicenter survey publication-title: Clin Res Cardiol doi: 10.1007/s00392-020-01722-w contributor: fullname: Rivinius – volume: 14 start-page: 1560 year: 2021 ident: 10.1016/j.transproceed.2022.02.022_bib0015 article-title: Antibodies against receptor binding domain of SARS-CoV-2 spike protein induced by BNT162b2 vaccine: results from a pragmatic, real-life study publication-title: J Infect Public Health doi: 10.1016/j.jiph.2021.06.020 contributor: fullname: Mariani – ident: 10.1016/j.transproceed.2022.02.022_bib0001 – year: 2021 ident: 10.1016/j.transproceed.2022.02.022_bib0007 article-title: SARS-CoV-2 infection after two doses of mRNA vaccine in renal transplant recipients publication-title: Transpl Infect Dis doi: 10.1111/tid.13628 contributor: fullname: Basic-Jukic – volume: 17 start-page: 785 year: 2021 ident: 10.1016/j.transproceed.2022.02.022_bib0012 article-title: COVID-19 vaccination in kidney transplant recipients publication-title: Nat Rev Nephrol doi: 10.1038/s41581-021-00491-7 contributor: fullname: Caillars – volume: 384 start-page: 1412 year: 2021 ident: 10.1016/j.transproceed.2022.02.022_bib0004 article-title: BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting publication-title: N Engl J Med doi: 10.1056/NEJMoa2101765 contributor: fullname: Dagan – volume: 27 start-page: 1173e year: 2021 ident: 10.1016/j.transproceed.2022.02.022_bib0006 article-title: Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2021.04.028 contributor: fullname: Rozen-Zvi – volume: 9 start-page: 52 year: 2021 ident: 10.1016/j.transproceed.2022.02.022_bib0010 article-title: COVID-19 in heart transplant recipients: a multicenter analysis of the Northern Italian outbreak publication-title: JACC Heart Fail doi: 10.1016/j.jchf.2020.10.009 contributor: fullname: Bottio – ident: 10.1016/j.transproceed.2022.02.022_bib0011 – volume: 10 start-page: 132 year: 2021 ident: 10.1016/j.transproceed.2022.02.022_bib0003 article-title: Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis publication-title: Infect Dis Poverty doi: 10.1186/s40249-021-00915-3 contributor: fullname: Liu – volume: 14 start-page: 2270 year: 2021 ident: 10.1016/j.transproceed.2022.02.022_bib0014 article-title: Factors associated with humoral response after BNT162b2 mRNA COVID-19 vaccination in kidney transplant patients publication-title: Clin Kidney J doi: 10.1093/ckj/sfab125 contributor: fullname: Ducloux – volume: 21 start-page: 3990 year: 2021 ident: 10.1016/j.transproceed.2022.02.022_bib0008 article-title: Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients publication-title: Am J Transplant doi: 10.1111/ajt.16818 contributor: fullname: Schmidt – volume: 385 start-page: 585 year: 2021 ident: 10.1016/j.transproceed.2022.02.022_bib0002 article-title: Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant publication-title: N Engl J Med doi: 10.1056/NEJMoa2108891 contributor: fullname: Lopez Bernal – volume: 74 start-page: 1093 year: 2021 ident: 10.1016/j.transproceed.2022.02.022_bib0013 article-title: Poor antibody response after two doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in transplant recipients publication-title: Clin Infect Dis doi: 10.1093/cid/ciab580 contributor: fullname: Mazzola |
| SSID | ssj0004243 |
| Score | 2.38201 |
| Snippet | Patients after orthotopic heart transplantation (HTx) are especially susceptible to infections owing to permanent need for immunosuppression. Vaccinations... BACKGROUNDPatients after orthotopic heart transplantation (HTx) are especially susceptible to infections owing to permanent need for immunosuppression.... |
| SourceID | pubmedcentral proquest crossref pubmed elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 897 |
| SubjectTerms | Adult Aged COVID-19 - prevention & control Heart Transplantation - adverse effects Humans Middle Aged mRNA Vaccines SARS-CoV-2 Vaccination Vaccines, Synthetic |
| Title | Patients After Orthotopic Heart Transplantation With COVID-19: Are We Fast Enough With Vaccinations? |
| URI | https://dx.doi.org/10.1016/j.transproceed.2022.02.022 https://www.ncbi.nlm.nih.gov/pubmed/35414424 https://search.proquest.com/docview/2649996482 https://pubmed.ncbi.nlm.nih.gov/PMC8920909 |
| Volume | 54 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1db9MwFLXKEBIvCDZg5UtGYnvpUiVOmg8khErXabywipUV8RI5jsM6tmRKUqH213Ntx0naadIQQqqiKHESp-fE9r2-9xihdwl1rShyAYHEjQ2HB9SgdsAMzj3ojSmFMbJIFD4-9b589w_HzrjT0atmNMf-K9JwDLAWmbN_gXZ9UzgA-4A5bAF12N4J94kSSi16Q7n690lenmdldj1nIuMoLys180uaVmGGM-GIHZ2cfT40rEC6CXPem_HeES3K3jiVi_jIMmeUsbnyHRYb4YCb92x6xdZUEVtROVM0_JmCdb76VfcHk3y1jJZ7o8GeT7Lf1Trak3lW5m2XBFizdQCg8pPpXJm1UE6h7GVYthKP7HPV3PqebRBXZRzr9liJSle8c1qNq68ieat-OpAKpze7AOWNuOiX8tXV-_ZFLaU2q0qC3pDYPhV1E1UjRM7MQpd-n0DDJdrNH4OvTZ4t0VGY6k20iK2MF7ztebcNeG4aNJtxua2BzvQxelRZKHioqPUEdXi6jXaGgHx2tcT7WMYMy8mYbfTgk97bnygN9OUBnjYpfcWBvKBWR1_uoFgTFEuC4oagWBIUb5AJC_JhTdD3UC-OZxwLemJFT1WiTc-PT9G3o_F0dGxUS30YzLG80kgSOzEji1KXewwIERMeMUbAPDEDEkVELooDlofJKI0Tk5HIiWFgL8IRYt-PA_sZ2kqzlO8izByhyWjGARgjThT5FE7HUeLHVsAT1-RdZGs8wmul6BLqUMeLsI1iKFAMTfEjXfRBQxdWY1M15gyBd3e6_q3GO4QGXMzK0ZRniyIEi0Q4HRwfyjxX-Nf1sgeO5QDrushbY0ZdQIjDr59J5-dSJN4PiAl_3ot_rPdL9LD5wl-hrTJf8NfoXhEv3shv4w_LguJ_ |
| link.rule.ids | 230,315,782,786,887,27933,27934 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Patients+After+Orthotopic+Heart+Transplantation+With+COVID-19%3A+Are+We+Fast+Enough+With+Vaccinations%3F&rft.jtitle=Transplantation+proceedings&rft.au=Kuczaj%2C+Agnieszka&rft.au=Przyby%C5%82owski%2C+Piotr&rft.date=2022-05-01&rft.pub=Elsevier+Inc&rft.issn=0041-1345&rft.eissn=1873-2623&rft.volume=54&rft.issue=4&rft.spage=897&rft.epage=900&rft_id=info:doi/10.1016%2Fj.transproceed.2022.02.022&rft.externalDocID=S0041134522002032 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-1345&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-1345&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-1345&client=summon |